<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-EPLERENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EPLERENONE" rxcui="298869">
<ATC code="C03DA04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hyperkalemia, especially with older patients</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict testing of the kalemia and of the renal function during the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-EPLERENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EPLERENONE" rxcui="298869">
<ATC code="C03DA04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>Increase of the risk of hyperkalemia, especially with older patients.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict testing of the kalemia and of the renal function during the administration of these substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>208-EPLERENONE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="EPLERENONE" rxcui="298869">
<ATC code="C03DA04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the plasma concentrations of the eplerenone by the inhibitor and of its undesirable effects, especially hyperkalemia</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
